

**Table EU Approved / positive opinion biosimilars by molecule April 2022**

(not available in all EU-countries) (status CHMP-meeting March21. 2022, 75 products, from which 3 pending EC approval\*)

Molecule	Reference	Biosimilar(s)
Adalimumab	Humira	Amgevita, Amsparity, Halimatoz, Hefiya, Hukyndra, Hulio, Hyrimoz, Idacio, Libmyris, Imraldi; Yuflyma (new formulation)
bevacizumab	Avastin	Abevmy, Alymsys, Aybinto, Equidacent; MVasi, Onbevzi, Oyavas, Zirabev
Enoxaparine	Clexane	Inhixa
Epoetine alfa	Eprex	Absaemed, Binocrit, Epoetin alfa Hexal, Retacrit, Silapo
Etanercept	Enbrel	Benepali, Erelzi, Nepexto
Filgrastim	Neupogen	Accofil, Filgrastim Hexal, Grastofil, Nivestim, Ratiograstim, Tevagrastim, Zarzio
Follitropin alfa	Gonal-f	Bemfola, Ovaleap
Infliximab	Remicade	Flixabi, Inflectra, Remsima, Zessly
Insulin Aspart	Novo Rapid	Insulin Aspart Sanofi; Kixelle, positive opinion: Truvelog Mix30*
Insulin glargine	Lantus	Abasaglar, Semglee
Insulin Human	Actrapid	Positive opinion: Inpremia*
Insulin Lispro	Humalog	Insulin Lispro Sanofi
Pegfilgrastim	Neulasta	Cegfila, Fulphila, Grasustek, Nyvepria, Pelgraz, Pelmeg, Stimulent, Udenyca, Ziextenzo
Ranibizumab	Lucentis	Byooviz
Rituximab	Mabthera IV	Blitzima, Ritemvia, Rixathon, Riximyo, Ruxience, Truxima
Somatropine	Genotropin	Omnitrope
Teriparatide	Forsteo	Movymia, Terrosa, Livogiga, positive opinion: Sondelbay*
Trastuzumab	Herceptin IV	Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac

Source: EMA website

[https://www.ema.europa.eu/medicines/field\\_ema\\_web\\_categories%253Aname\\_field/Human/ema\\_group\\_types/ema\\_a\\_medicine/field\\_ema\\_med\\_status/authorised36/ema\\_medicine\\_types/field\\_ema\\_med\\_biosimilar/search\\_api\\_aggregation\\_ema\\_medicine\\_types/field\\_ema\\_med\\_biosimilar](https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_a_medicine/field_ema_med_status/authorised36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar)

Accessed: April 1, 2022\_LB

13 Biosimilar-products in the licensing pipeline at EMA (Status: April 6, 2022).

Bevacizumab (1x), Eculizumab (1x), Eptacog alfa (activated) (1x), Filgrastim (1x), pegfilgrastim (2x), ranibizumab (2x), teriparatide (1x), trastuzumab (3x).

For a comparison with US/FDA (March 2022) see:

<https://www.biosimilarsip.com/2022/03/14/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-updated-march-14-2022/>

FDA approved biosimilars (status May1, 2022)

<https://biosimilarsrr.com/us-biosimilar-filings/>